Recent development in CRISPR-Cas systems for human protozoan diseases DOI

Utkarsh Gangwar,

Himashree Choudhury,

Risha Shameem

et al.

Progress in molecular biology and translational science, Journal Year: 2024, Volume and Issue: unknown, P. 109 - 160

Published: Jan. 1, 2024

Language: Английский

A new member of the dynamin superfamily modulates mitochondrial membrane branching in Trypanosoma brucei DOI Creative Commons
Chloé Morel, Corinne Asencio, David Moreira

et al.

Current Biology, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Unlike most other eukaryotes, where mitochondria continuously fuse and divide, the mitochondrion of trypanosome cells forms a single interconnected network that divides only during cytokinesis. However, machinery governing mitochondrial remodeling interconnection remain largely unknown. We functionally characterize new member dynamin superfamily protein (DSP) from T. brucei (TbMfnL), which shares similarity with family homologs present in various eukaryotic prokaryotic phyla but not opisthokonts like mammals budding yeast. The sequence domain organization TbMfnL is distinct, it phylogenetically very distant yeast mammalian dynamin-related proteins involved fusion/fission dynamics, such as optic atrophy 1 (Opa1) mitofusin (Mfn). localizes to inner membrane facing matrix and, upon overexpression, induces strong increase branching filaments GTPase-dependent manner. component novel an unprecedented matrix-side localization able modulate degree inter-mitochondrial connections.

Language: Английский

Citations

1
Advancements and challenges in mRNA and ribonucleoprotein-based therapies: From delivery systems to clinical applications DOI Creative Commons

Zohre Eftekhari,

Horieh Zohrabi,

Akbar Oghalaie

et al.

Molecular Therapy — Nucleic Acids, Journal Year: 2024, Volume and Issue: 35(3), P. 102313 - 102313

Published: Aug. 19, 2024

The use of mRNA and ribonucleoproteins (RNPs) as therapeutic agents is a promising strategy for treating diseases such cancer infectious diseases. This review provides recent advancements challenges in mRNA- RNP-based therapies, focusing on delivery systems lipid nanoparticles (LNPs), which ensure efficient to target cells. Strategies microfluidic devices are employed prepare LNPs loaded with RNPs, demonstrating effective genome editing protein expression vitro vivo. These applications extend treatment disease management, results therapy using encapsulating Cas9 single-guide RNA. In addition, tissue-specific targeting strategies offer potential improved outcomes reduced off-target effects. Despite progress, optimizing efficiency remain. Future research should enhance efficiency, explore targeting, investigate combination advance clinical translation. conclusion, therapies avenue various have the revolutionize medicine, providing new hope patients worldwide.

Language: Английский

Citations

4
CRISPR-Cas in Parasites: Advances and Challenges in the Study of Neglected Tropical Diseases DOI
Ana María Mejía‐Jaramillo, Omar Triana‐Chávez

Published: Jan. 1, 2025

Language: Английский

Citations

0
PUF3 RNA binding protein of Trypanosoma cruzi regulates mitochondrial morphology and function DOI Creative Commons
Ana María Mejía‐Jaramillo, Geysson Javier Fernández,

Hader Ospina-Zapata

et al.

Heliyon, Journal Year: 2024, Volume and Issue: 10(12), P. e32810 - e32810

Published: June 1, 2024

The RNA-binding PUF proteins are post-transcriptional regulators found throughout the eukaryotic domain. In

Language: Английский

Citations

2
Recent development in CRISPR-Cas systems for human protozoan diseases DOI

Utkarsh Gangwar,

Himashree Choudhury,

Risha Shameem

et al.

Progress in molecular biology and translational science, Journal Year: 2024, Volume and Issue: unknown, P. 109 - 160

Published: Jan. 1, 2024

Language: Английский

Citations

0